Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An anti-gamma-delta TCR antibody is a monoclonal antibody designed to target the gamma-delta T-cell receptor (γδ TCR) on the surface of gamma-delta T cells. γδ T cells are a unique subset of T lymphocytes that bridge innate and adaptive immunity, playing critical roles in tumor surveillance, mucosal defense, and autoimmune regulation. Depending on the specific clone and context, anti-γδ TCR antibodies can be used to deplete γδ T cells in vivo, block their activation, or conversely, stimulate their proliferation and effector functions for cancer immunotherapy. These antibodies are widely utilized as research reagents in preclinical models of cancer, infection, and autoimmunity, and are also being explored as therapeutic platforms to redirect γδ T-cell cytotoxicity against tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-gamma-delta TCR antibody.